Insulet Corporation announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, marking its 20th market for Omnipod 5 and 26th country for Omnipod products. The expansion supports the company's goal of broadening access to its tubeless insulin delivery technology. Separately, Evercore ISI lowered its price target on Insulet to $180 from $200 while maintaining an Outperform rating, citing generally positive industry trends in its second-quarter MedTech preview.
Insulet CorporationCommercial launch of Omnipod 5 in Spain expands market reach and potential customer base.
Evercore Partners Inc